Caribou Biosciences Inc
For the period ended Mar 31, 2024. Filed May 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 7, 2024
CRBU$0.41-2.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
(in thousands, except share amounts)
| Common Stock · Additional Paid-InCapital · Accumulated Other Comprehensive Income (Loss) · Accumulated Deficit · Total Stockholders’ Equity | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| BALANCE—December 31, 2023 | 88,448,948 | $8 | $667,648 | $30 | $(299,285) | $368,401 |
| Issuance of common stock upon employee stock plans | 122,035 | — | 667 | — | — | 667 |
| Issuance of common stock on exercise of options | 134,347 | — | 489 | — | — | 489 |
| Issuance of common stock in connection with our at-the-market equity offering program, net of offering expenses | 1,594,171 | 1 | 11,329 | — | — | 11,330 |
| Issuance of common stock on RSU release | 15,000 | — | — | — | — | — |
| Stock-based compensation expense | — | — | 3,988 | — | — | 3,988 |
| Net loss | — | — | — | — | (41,234) | (41,234) |
| Other comprehensive loss | — | — | — | (352) | — | (352) |
| BALANCE—March 31, 2024 | 90,314,501 | $9 | $684,121 | $(322) | $(340,519) | $343,289 |
| BALANCE—December 31, 2022 | 61,029,184 | $6 | $499,598 | $(1,518) | $(197,215) | $300,871 |
| Issuance of common stock under employee stock plans | 70,271 | — | 404 | — | — | 404 |
| Issuance of common stock on exercise of options | 55,433 | — | 115 | — | — | 115 |
| Issuance of common stock in connection with our at-the-market equity offering program, net of offering expenses | 168,635 | — | 1,007 | — | — | 1,007 |
| Stock-based compensation expense | — | — | 3,131 | — | — | 3,131 |
| Net loss | — | — | — | — | (28,044) | (28,044) |
| Other comprehensive income | — | — | — | 788 | — | 788 |
| BALANCE—March 31, 2023 | 61,323,523 | $6 | $504,255 | $(730) | $(225,259) | $278,272 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.